

Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-274 (canceled)

Claims 275 – 283 (canceled)

Claim 284. (original) A combination of dosage amounts of pharmaceutical compositions comprising:

- (1) a first non-toxic dosage amount of a pharmaceutical composition in a form for systemic administration to a human comprising:
 - (i) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof, and combinations thereof, having a molecular weight less than 750,000 daltons,
 - (ii) a drug selected from the group consisting of:
 - a) a non-steroidal anti-inflammatory drug (NSAID),
 - (b) a chemotherapeutic agent, and
 - (c) combinations thereof, and optionally,
 - (iii) an anti-oxidant; and
- (2) a second non-toxic dosage amount of a pharmaceutical composition in a form for injection into a human comprising:
 - (i) an anti-cancer drug and/or drug suitable for use to treat cancer, and
 - (ii) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof, and combinations thereof, wherein the form of hyaluronic acid has a molecular weight less than 750,000 daltons and is in sterile water, wherein the first and second non-toxic dosage amounts are not the same.

Claim 285. (original) The combination of claim 284, wherein the drug in the first dosage amount is an NSAID.

Claim 286. (original) The combination of claim 284, wherein the form of hyaluronic acid in the first and/or second non-toxic dosage amount is sodium hyaluronate.

Claim 287. (canceled)

Claim 288. (original) A combination of dosage amounts of pharmaceutical compositions comprising:

- (1) a first non-toxic dosage amount of a pharmaceutical composition in a form for systemic administration to a human comprising
 - (i) sodium hyaluronate having a molecular weight less than 750,000 daltons; and
 - (ii) a drug selected from the group consisting of:
 - (a) diclofenac sodium,
 - (b) novantrone, and
 - (c) combinations thereof, and, optionally,
 - (ii) Vitamin C, and
- (2) a second non-toxic dosage amount of a pharmaceutical composition for injection into a human comprising novantrone and/or a drug suitable for use to treat cancer and sodium hyaluronate in sterile water having a molecular weight less than 750,000 daltons.

Claims 289 – 296 (canceled).